Literature DB >> 9618423

Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.

R C Pitts1, R M Allen, E A Walker, L A Dykstra.   

Abstract

The opioid agonists morphine, etorphine, buprenorphine and U50,488 were examined alone and in combination with the insurmountable opioid antagonist clocinnamox (C-CAM) in squirrel monkeys responding under a schedule of shock titration. In this procedure, shock intensity increased every 15 sec from 0.01 to 2.0 mA in 30 increments. Five lever presses during any given 15-sec shock period produced a 15-sec timeout, after which shock resumed at the next lower intensity. When given alone, each of these agonists increased the median intensity at which the monkeys maintained shock [median shock level (MSL)]. At the highest dose examined alone, each agonist produced maximal increases in MSL and, except buprenorphine, decreased response rates. C-CAM dose-dependently antagonized the effects of morphine, etorphine and buprenorphine on MSL. In the presence of the higher C-CAM doses, etorphine, morphine and buprenorphine did not produce maximal effects on MSL. The effects of U50,488 were not systematically altered when tested in combination with the highest C-CAM dose. In general, C-CAM was more potent and the duration of antagonism was slightly longer against buprenorphine than against morphine and etorphine. Quantitative analysis of these data according to an extended model of yielded the following apparent affinity and efficacy estimates, respectively: etorphine (0. 085 mg/kg, 117); morphine (49 mg/kg, 24) and buprenorphine (0.62 mg/kg, 7.1). Determination of the individual q values over time indicated that the receptor population recovers more quickly after C-CAM antagonism of etorphine than from C-CAM antagonism of either morphine or buprenorphine. These data suggest that C-CAM functions as a long-lasting antagonist of mu opioid agonist actions in a shock titration procedure and yields estimates of relative intrinsic efficacy with the rank order of etorphine > morphine > buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618423

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.

Authors:  Sandra D Comer; Maria A Sullivan; Ellen A Walker
Journal:  J Pharmacol Exp Ther       Date:  2005-09-06       Impact factor: 4.030

Review 2.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

3.  The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

Authors:  Heather Cox; Daniel M Togasaki; Li Chen; J William Langston; Donato A Di Monte; Maryka Quik
Journal:  Exp Neurol       Date:  2007-02-03       Impact factor: 5.330

4.  Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

Authors:  Sandra D Comer; Ellen A Walker; Eric D Collins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

5.  Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Authors:  Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

6.  Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Authors:  Jeremy C Cornelissen; Samuel Obeng; Kenner C Rice; Yan Zhang; S Stevens Negus; Matthew L Banks
Journal:  J Pharmacol Exp Ther       Date:  2018-01-12       Impact factor: 4.030

7.  Effect of Interleukin-1β on Gene Expression Signatures in Schwann Cells Associated with Neuropathic Pain.

Authors:  Yanhan Ma; Hanliang Sun; Shuhong An; Zhaojin Wang
Journal:  Neurochem Res       Date:  2021-07-15       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.